U.S. pharma large copyright scrapped two experimental weight loss products previous year—a at the time-every day pill, lotiglipron, as a result of elevated liver enzymes plus a two times-each day capsule, danuglipron, as a result of potent Negative effects—but CEO Albert Bourla has claimed the company is set to “Participate in and win” in t